Connection | Profiles RNS

Search Result Details

Back to Search Results

This page shows the details of why an item matched the keywords from your search.

Search Results

COLEMAN, ROBERT

One or more keywords matched the following items that are connected to COLEMAN, ROBERT

Item Type	Name
Concept	Angiogenesis Inhibitors
Academic Article	Summary of the 2014 MD Anderson International Meeting in Gynecologic Oncology: emerging therapies in gynecologic cancer.
Academic Article	Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma.
Academic Article	Dual targeting of EphA2 and FAK in ovarian carcinoma.
Academic Article	Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.
Academic Article	Therapeutic advances in women's cancers.
Academic Article	Targeting angiogenesis in gynecologic cancers.
Academic Article	Antitumor and antivascular effects of AVE8062 in ovarian carcinoma.
Academic Article	Angiogenesis as a strategic target for ovarian cancer therapy.
Academic Article	Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds.
Academic Article	Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer.
Academic Article	Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.
Academic Article	Moving beyond anti-vascular endothelial growth factor therapy in ovarian cancer.
Academic Article	Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies.
Academic Article	Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.
Academic Article	Clinical and biological significance of vascular endothelial growth factor in endometrial cancer.
Academic Article	Impact of vessel maturation on antiangiogenic therapy in ovarian cancer.
Academic Article	Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer.
Academic Article	Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.
Academic Article	Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer.
Academic Article	Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors.
Academic Article	Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma.
Academic Article	Emerging strategies in bone health management for the adjuvant patient.
Academic Article	Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer.
Academic Article	New ways to successfully target tumor vasculature in ovarian cancer.
Academic Article	Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.
Academic Article	In assessing surrogate clinical trial end points: drug safety is a requisite.
Academic Article	Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.
Academic Article	Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer.
Academic Article	Targeting the tumour microenvironment in ovarian cancer.
Academic Article	Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience.
Academic Article	Management and Treatment of Recurrent Epithelial Ovarian Cancer.
Academic Article	Anti-Angiogenesis Therapy in Ovarian Cancer: Which Patient is It Most Likely to Benefit?
Academic Article	Bevacizumab (Avastin?) in cancer treatment: A review of 15?years of clinical experience and future outlook.
Academic Article	Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.
Academic Article	Selecting new upfront regimens for advanced ovarian cancer with biomarker guidance.

Search Criteria

Angiogenesis Inhibitors